MedTrace Logo

Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154

NCT05837338 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-07-29

No results posted yet for this study

Summary

The goal of this clinical trial is to test if the study drug, BXP154 works to stop bleeding from a minor wound in patients that are on anticoagulant therapy. The main questions it aims to answer are:

* How long does it take to stop bleeding after BXP154 is applied to a wound?
* How many people require the use of a rescue treatment to stop bleeding?
* Does BXP154 reduce instances of re-bleeding after the bleeding has stopped initially?
* Is BXP154 safe and well-tolerated?

Conditions

  • Wound Bleeding

Interventions

DRUG

BXP154

BXP154 will be self-administered topically following wound induction

DRUG

Placebo

Placebo will be self-administered topically following wound induction

Sponsors & Collaborators

  • Bio 54, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2023-07-26
Completion
2023-07-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05837338 on ClinicalTrials.gov